Anti-cancer

articles with this tag

Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.

READ ARTICLE

PTX Breast Cancer Trial Results Exceed Industry Expectations

PTX Breast Cancer Trial Results Exceed Industry Expectations

Prescient Therapeutics (ASX:PTX) is looking to prove up its two breast cancer therapies, putting it ahead of the field in areas of high unmet need.

READ ARTICLE

ASX Junior at the Forefront of Cancer Research Could be Set for a Blockbuster Year

ASX Junior at the Forefront of Cancer Research Could be Set for a Blockbuster Year

This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.

READ ARTICLE

IMU Picks up the Pace in Cancer Drug Treatment Development

IMU Picks up the Pace in Cancer Drug Treatment Development

It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.

READ ARTICLE

Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets

Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets

If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.

READ ARTICLE

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.

READ ARTICLE

CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry

CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry

Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.

READ ARTICLE

NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks

NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks

Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.

READ ARTICLE

New ASX Listing to Turbo Charge Treatment in $100BN Oncology Market

New ASX Listing to Turbo Charge Treatment in $100BN Oncology Market

The weird and wonderful world of Biotechnology has a lot going for it — an industry working at the sharp-end of breakthrough medical research, Biotech is also one of the more enticing investment landscapes of modern times. In how many other industries are companies literally striving to save lives?

READ ARTICLE

New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.

READ ARTICLE

$26M Capped ASX Stock Generating Millions in Revenue: US and Chinese Markets are Next

$26M Capped ASX Stock Generating Millions in Revenue: US and Chinese Markets are Next

With a total global market of $90 billion, successful hair loss products can generate hundreds of millions of dollars in revenue. However the current market leaders may soon be under pressure from one particular ASX listed life sciences company.

READ ARTICLE

Medical Cannabis First Mover: MMJ to Accelerate Australian Roll Out

Medical Cannabis First Mover: MMJ to Accelerate Australian Roll Out

The long term game that emerging medical cannabis company MMJ PhytoTech (ASX:MMJ) is playing is gradually paying off.

READ ARTICLE